AIM
Income statement / Annual
Last year (2023), AIM ImmunoTech Inc.'s total revenue was $202,000.00,
an increase of 43.26% from the previous year.
In 2023, AIM ImmunoTech Inc.'s net income was -$28.96 M.
See AIM ImmunoTech Inc.’s key income statements, including revenue, expenses, profit, and income.
Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
Operating Revenue |
$202,000.00
|
$141,000.00
|
$135,000.00
|
$163,000.00
|
$140,000.00
|
$367,000.00
|
$437,000.00
|
$92,000.00
|
$133,000.00
|
$197,000.00
|
Cost of Revenue |
$42,000.00 |
$19.92 M |
$850,000.00 |
$806,000.00 |
$893,000.00 |
$884,000.00 |
$1.18 M |
$1.11 M |
$1.60 M |
$1.25 M |
Gross Profit |
$160,000.00 |
-$19.78 M |
-$715,000.00 |
-$643,000.00 |
-$753,000.00 |
-$517,000.00 |
-$746,000.00 |
-$1.02 M |
-$1.47 M |
-$1.05 M |
Gross Profit Ratio |
0.79 |
-140.3 |
-5.3 |
-3.94 |
-5.38 |
-1.41 |
-1.71 |
-11.04 |
-11.02 |
-5.35 |
Research and Development
Expenses |
$10.94 M
|
$6.99 M
|
$7.67 M
|
$5.72 M
|
$4.65 M
|
$4.78 M
|
$4.10 M
|
$5.11 M
|
$8.04 M
|
$8.99 M
|
General & Administrative
Expenses |
$21.14 M
|
$13.07 M
|
$8.67 M
|
$8.65 M
|
$7.04 M
|
$6.20 M
|
$6.57 M
|
$7.68 M
|
$7.15 M
|
$9.06 M
|
Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
Selling, General &
Administrative Expenses |
$21.14 M
|
$13.07 M
|
$8.67 M
|
$8.65 M
|
$7.04 M
|
$6.20 M
|
$6.57 M
|
$7.68 M
|
$7.15 M
|
$9.06 M
|
Other Expenses |
$0.00 |
$1.49 M |
$2.32 M |
$1.19 M |
$866,000.00 |
$277,000.00 |
$3.21 M |
$2.87 M |
$1.37 M |
$1.13 M |
Operating Expenses |
$32.08 M |
$20.06 M |
$16.34 M |
$14.37 M |
$11.69 M |
$10.98 M |
$10.67 M |
$12.79 M |
$15.19 M |
$18.05 M |
Cost And Expenses |
$32.12 M |
$20.06 M |
$17.19 M |
$15.18 M |
$12.58 M |
$11.86 M |
$11.85 M |
$13.90 M |
$16.78 M |
$19.30 M |
Interest Income |
$0.00 |
$629,000.00 |
$67,000.00 |
$219,000.00 |
$89,000.00 |
$46,000.00 |
$88,000.00 |
$129,000.00 |
$364,000.00 |
$665,000.00 |
Interest Expense |
$0.00 |
$0.00 |
$67,000.00 |
$672,000.00 |
$427,000.00 |
$502,000.00 |
$139,000.00 |
$129,000.00 |
$3,000.00 |
$11,000.00 |
Depreciation &
Amortization |
$238,000.00
|
-$424,000.00
|
$805,000.00
|
$706,000.00
|
$829,000.00
|
$920,000.00
|
$1.00 M
|
$1.17 M
|
$1.19 M
|
$1.14 M
|
EBITDA |
-$31.68 M
|
-$19.87 M
|
-$18.26 M
|
-$13.02 M
|
-$8.15 M
|
-$8.41 M
|
-$7.12 M
|
-$6.33 M
|
-$14.25 M
|
-$16.74 M
|
EBITDA Ratio |
-156.82 |
-124.45 |
-103.44 |
-79.01 |
-76.4 |
-28.05 |
-16.27 |
-134.48 |
-113.5 |
-87.78 |
Operating Income Ratio
|
-158
|
-141.3
|
-139.54
|
-92.96
|
-88.88
|
-31.32
|
-26.12
|
-150.04
|
-125.19
|
-96.95
|
Total Other
Income/Expenses Net |
$2.95 M
|
$478,000.00
|
-$289,000.00
|
$752,000.00
|
$3.04 M
|
$1.67 M
|
$3.16 M
|
$6.30 M
|
$1.42 M
|
$1.65 M
|
Income Before Tax |
-$28.96 M |
-$19.45 M |
-$19.13 M |
-$14.40 M |
-$9.53 M |
-$9.81 M |
-$8.26 M |
-$7.50 M |
-$15.23 M |
-$17.45 M |
Income Before Tax Ratio
|
-143.38
|
-137.91
|
-141.68
|
-88.34
|
-68.09
|
-26.74
|
-18.9
|
-81.54
|
-114.51
|
-88.58
|
Income Tax Expense |
$0.00 |
$1.64 M |
$2.39 M |
$1.86 M |
$1.29 M |
$2.19 M |
$3.35 M |
$134,000.00 |
$3,000.00 |
$11,000.00 |
Net Income |
-$28.96 M |
-$21.09 M |
-$21.51 M |
-$16.26 M |
-$10.83 M |
-$9.81 M |
-$8.26 M |
-$7.50 M |
-$15.23 M |
-$17.45 M |
Net Income Ratio |
-143.38 |
-149.55 |
-159.36 |
-99.74 |
-77.33 |
-26.74 |
-18.9 |
-81.54 |
-114.51 |
-88.58 |
EPS |
-0.6 |
-0.44 |
-0.45 |
-0.51 |
-2.97 |
-9.77 |
-12.67 |
-15.13 |
-34.05 |
-48.93 |
EPS Diluted |
-0.6 |
-0.44 |
-0.45 |
-0.51 |
-2.97 |
-9.77 |
-12.67 |
-15.13 |
-34.05 |
-48.93 |
Weighted Average Shares
Out |
$48.59 M
|
$48.05 M
|
$47.34 M
|
$31.84 M
|
$3.64 M
|
$1.00 M
|
$651,721.00
|
$495,862.00
|
$447,251.00
|
$356,609.00
|
Weighted Average Shares
Out Diluted |
$48.59 M
|
$48.05 M
|
$47.34 M
|
$31.84 M
|
$3.64 M
|
$1.00 M
|
$651,721.00
|
$495,862.00
|
$447,251.00
|
$356,609.00
|
Link |
|
|
|
|
|
|
|
|
|
|